CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

This study is testing a new CAR-T cell therapy that targets a protein called CD70 in people with relapsed or refractory lymphoma (lymphoma that has come back or stopped responding to treatment). CAR-T therapy involves modifying a patient's own immune cells to recognize and attack cancer cells. **You may be eligible if...** - You are between 18 and 75 years old with a confirmed diagnosis of lymphoma (including Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or other types) - Your lymphoma has relapsed after at least 2 prior treatments - Your cancer cells express the CD70 protein (at least 10% positive on testing) - Your overall health and organ function meet the required levels **You may NOT be eligible if...** - You are HIV-positive or have active hepatitis B or C - You have had a prior organ or stem cell transplant from a donor - You have cancer involving the brain - You have had another cancer within the past 5 years (except certain early-stage skin or cervical cancers) - You received recent cancer treatment or are on immune-suppressing medications Talk to your doctor to see if this trial is right for you.